Plovamer

Drug Profile

Plovamer

Alternative Names: CO-14; PI-2301

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Harvard University; Peptimmune
  • Developer EMD Serono; Peptimmune
  • Class Amino acids; Peptides
  • Mechanism of Action Major histocompatibility complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • Discontinued Crohn's disease; Rheumatoid arthritis; Uveitis

Most Recent Events

  • 29 Oct 2013 Phase-II clinical trials in Multiple sclerosis in Italy (SC)
  • 29 Oct 2013 Phase-II clinical trials in Multiple sclerosis in USA (SC)
  • 19 Sep 2011 Plovamer licensed to Merck Serono worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top